文献速递角膜与眼表疾病小儿眼科与斜弱视

环孢素A阳离子乳剂治疗儿童春季角结膜炎的随机对照试验:VEKTIS研究

A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: The VEKTIS Study.
PubMed 文献 · Ophthalmology · 2018-12-27

主要终点为反映角膜荧光素染色(CFS)、补救药物使用和角膜溃疡的复合评分,高剂量组与赋形剂组差异有统计学意义(0.76;P=0.007),低剂量组亦显著(0.67;P=0.010),治疗效应主要来自CFS评分。高剂量CsA CE在改善角膜炎、症状和生活质量方面有效,且耐受性良好。

要点

  • 高剂量CsA CE 0.1%每日4次治疗4个月显著改善重度VKC患儿主要复合终点。
  • 低剂量CsA CE每日2次亦显著优于赋形剂,但治疗效应主要来自角膜荧光素染色评分。
  • 高剂量CsA CE在改善症状和生活质量方面显著优于赋形剂,且耐受性良好。

核心结论

  • 高剂量CsA CE 0.1%每日4次可改善重度VKC患儿的角膜炎、症状和生活质量,且耐受性良好。

主要发现

  • 主要终点最小二乘均值与赋形剂差值:高剂量组0.76(P=0.007),低剂量组0.67(P=0.010),治疗效应主要来自CFS评分。
  • 两个活性治疗组与赋形剂组在补救药物使用方面均存在显著差异。
  • 三组VKC症状和患者生活质量均有改善,高剂量CsA CE组较赋形剂组改善显著。

关键数值与推荐

  • 入组标准为Bonini严重度量表3或4级且改良Oxford量表CFS评分为4或5的重度VKC患儿。
  • 高剂量方案为CsA CE 0.1%(1 mg/ml)每日4次,低剂量方案为每日2次加赋形剂每日2次,对照为赋形剂每日4次。
  • 补救药物为地塞米松0.1%每日4次。

临床怎么用

  • 对4至18岁以下重度VKC患儿,可考虑高剂量CsA CE 0.1%每日4次治疗以改善角膜炎、症状和生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Vernal keratoconjunctivitis (VKC) is a chronic, allergic, and potentially severe ocular disease affecting children and adolescents that can lead to impaired quality of life (QoL) and loss of vision. This study evaluated the efficacy and safety of an investigational therapy for severe VKC, cyclosporine A (CsA) cationic emulsion (CE), an oil-in-water emulsion with increased bioavailability versus conventional CsA formulations. DESIGN: The VErnal KeratoconjunctiviTIs Study (VEKTIS) is a phase 3, multicenter, double-masked, vehicle-controlled trial. PARTICIPANTS: Pediatric patients (4 to younger than 18 years) with active severe VKC (grade of 3 or 4 on the Bonini severity scale) and severe keratitis (corneal fluorescein staining [CFS] score of 4 or 5 on the modified Oxford scale). METHODS: One hundred sixty-nine patients were randomized to CsA CE 0.1% (1 mg/ml) eye drops 4 times daily (high dose), CsA CE twice daily (low dose) plus vehicle twice daily, or vehicle 4 times daily for 4 months. MAIN OUTCOME MEASURES: The primary end point was a mean composite score that reflected CFS, rescue medication use (dexamethasone 0.1% 4 times daily), and corneal ulceration over the 4 months. RESULTS: Differences in least-squares means versus vehicle for the primary end point were statistically significant for both the high-dose (0.76; P = 0.007) and the low-dose (0.67; P = 0.010) groups, with treatment effect mainly driven by CFS score. Significant differences were found between both active treatment groups and vehicle for use of rescue medication. Vernal keratoconjunctivitis symptoms and patient QoL (assessed by visual analog scale and the Quality of Life in Children with Vernal Keratoconjunctivitis questionnaire) improved in all 3 groups, with significant improvements for high-dose CsA CE versus vehicle. CONCLUSIONS: The efficacy of high-dose CsA CE in improving keratitis, symptoms, and QoL for those with severe VKC was demonstrated in these study patients. In addition, in this study cohort, CsA CE was well tolerated.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Leonardi A, Doan S, Amrane M, et al. A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: The VEKTIS Study. Ophthalmology. 2018. PMID: 30593775. doi:10.1016/j.ophtha.2018.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。